Wendy Carruthers Sells 6,983 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares in the company, valued at approximately $2,978,734.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Wendy Carruthers also recently made the following trade(s):

• On Monday, July 1st, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90.
• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39.

Boston Scientific Stock Performance

Shares of BSX stock traded up $1.28 during trading hours on Thursday, reaching $75.16. 5,946,248 shares of the company traded hands, compared to its average volume of 6,339,827. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $79.43. The company has a market cap of $110.27 billion, a P/E ratio of 62.67, a P/E/G ratio of 2.45 and a beta of 0.78. The firm has a 50-day moving average price of $76.43 and a 200 day moving average price of $70.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. Boston Scientific’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 EPS. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised their target price on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, July 25th. TD Cowen boosted their target price on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Truist Financial lifted their price target on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Argus upped their price objective on shares of Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Boston Scientific from $83.00 to $88.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $84.76.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds have recently made changes to their positions in the company. Louisiana State Employees Retirement System bought a new stake in shares of Boston Scientific in the 4th quarter worth about $5,116,000. Sierra Summit Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $8,038,000. TD Asset Management Inc boosted its holdings in shares of Boston Scientific by 10.7% in the 4th quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after purchasing an additional 155,565 shares during the period. HealthInvest Partners AB bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $3,746,000. Finally, BI Asset Management Fondsmaeglerselskab A S raised its holdings in Boston Scientific by 225.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after buying an additional 73,219 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.